Shingles Vaccine Linked to Slower Biological Aging in Older Adults, USC Research Suggests

A groundbreaking study from the USC Leonard Davis School of Gerontology has unveiled compelling evidence that the shingles vaccine may offer benefits far beyond its primary role of preventing a painful rash. New research suggests a significant association between receiving the shingles vaccine and a slower rate of biological aging in older adults, marking a potential paradigm shift in understanding the broader health implications of adult vaccinations. This discovery could position vaccination as a proactive strategy in the fight against age-related decline, promoting resilience and extending healthspan.

Deciphering the Rhythms of Aging: Biological Versus Chronological

To fully appreciate the significance of this research, it’s crucial to distinguish between chronological age and biological age. Chronological age simply refers to the number of years a person has lived. Biological age, conversely, reflects the true physiological state of an individual’s body, encompassing the functional integrity of their organs, tissues, and cellular processes. It’s a measure of how well the body’s systems are functioning, irrespective of the birth certificate. Two individuals who are both 65 years old chronologically can exhibit vastly different biological profiles; one might possess the cellular vitality and organ function akin to a much younger person, while the other might show markers of accelerated aging, increasing their susceptibility to age-related diseases. This divergence underscores the importance of biological age as a more accurate predictor of health and longevity.

The field of gerontology has increasingly focused on biological aging as a critical determinant of healthy aging. Factors like genetics, lifestyle, environmental exposures, and chronic diseases all contribute to how quickly or slowly an individual’s biological clock ticks. Understanding and, more importantly, influencing biological aging pathways is a central goal for researchers aiming to extend not just lifespan, but "healthspan"—the period of life spent in good health, free from chronic diseases and disability.

The USC Study: Methodology and Revelations

The research, spearheaded by Jung Ki Kim, Research Associate Professor of Gerontology and the study’s first author, and coauthor Eileen Crimmins, USC University Professor and AARP Professor of Gerontology, leveraged data from the nationally representative U.S. Health and Retirement Study (HRS). The HRS is an invaluable longitudinal panel study that surveys a representative sample of approximately 20,000 Americans over the age of 50 every two years, providing a rich source of information on health, economic status, and social circumstances.

For this particular study, scientists focused on a robust cohort of more than 3,800 adults who were 70 years of age or older in 2016. This age group is particularly relevant as it represents a demographic where the impacts of aging become more pronounced and where the shingles vaccine is widely recommended. A meticulous analytical approach was employed, carefully accounting for potential confounding variables such as pre-existing health conditions, socioeconomic status, lifestyle factors, and other demographic differences that could influence aging rates. This rigorous statistical adjustment strengthens the credibility of the findings, suggesting that the observed association is not merely a byproduct of other health-related behaviors or circumstances.

The researchers evaluated a comprehensive set of seven distinct biological aging markers, which, when combined, provided an overall biological aging score. While the specific markers were not exhaustively detailed in the initial report, standard measures in gerontology research typically include:

1. C-reactive protein (CRP): A key inflammatory marker.
2. Albumin: Reflects liver function and nutritional status.
3. Creatinine: An indicator of kidney function.
4. Glucose: Blood sugar levels, linked to metabolic health.
5. Total Cholesterol: A measure of lipid metabolism.
6. White Blood Cell Count (WBC): General immune system activity.
7. Mean Corpuscular Volume (MCV): Red blood cell size, which can correlate with aging processes.

Beyond these traditional markers, the study also delved into more advanced indicators of cellular aging, specifically epigenetic aging and transcriptomic aging. Epigenetic aging refers to changes in gene expression without alterations to the underlying DNA sequence, often measured using "epigenetic clocks" that predict biological age with remarkable accuracy. Transcriptomic aging, on the other hand, examines the patterns of gene activity (RNA transcripts) within cells, offering insights into which genes are being turned on or off as a person ages.

The results were striking: participants who had received the shingles vaccine exhibited significantly lower levels of inflammation, slower epigenetic aging, slower transcriptomic aging, and, consequently, better overall biological aging scores compared to their unvaccinated counterparts. These findings illuminate a potential mechanism through which immune health, bolstered by vaccination, can exert a profound influence on the complex cascade of the aging process.

The Shingles Menace: A Background and its Prevention

To contextualize the vaccine’s impact, it is essential to understand shingles itself. Also known as herpes zoster, shingles is a debilitating and often excruciatingly painful rash characterized by fluid-filled blisters. It arises from the reactivation of the varicella-zoster virus (VZV), the same pathogen responsible for chickenpox. After an initial chickenpox infection, the VZV does not leave the body but rather lies dormant in nerve cells, often for decades. Anyone who has had chickenpox, which includes over 95% of adults born before 1980, carries this latent virus and is therefore at risk of developing shingles.

The risk of shingles significantly escalates after the age of 50, primarily due to the natural decline in immune function that accompanies aging, a phenomenon known as immunosenescence. Individuals with weakened immune systems, whether due to illness (like HIV/AIDS or cancer), medical treatments (like chemotherapy or immunosuppressants), or significant stress, are also at a higher risk, regardless of age.

The acute phase of shingles can last for several weeks, marked by severe pain, itching, and burning sensations. However, for a substantial proportion of patients, the pain can persist long after the rash has cleared, a condition known as postherpetic neuralgia (PHN). PHN is a chronic nerve pain that can be incredibly debilitating, impacting quality of life, sleep, and mental health for months or even years. The severity and duration of PHN are key reasons why shingles vaccination is so strongly recommended.

A Timeline of Shingles Vaccination:

• 1995: The Varicella (chickenpox) vaccine is approved in the U.S., significantly reducing childhood chickenpox cases.
• 2006: Zostavax, the first shingles vaccine, is approved by the FDA. It was a live attenuated vaccine, recommended for adults 60 and older. While effective, its efficacy waned over time and was lower in older age groups.
• 2017: Shingrix, a recombinant zoster vaccine, receives FDA approval. This non-live vaccine demonstrated superior efficacy (over 90%) across all age groups 50 and older and offered longer-lasting protection compared to Zostavax. Its introduction revolutionized shingles prevention.
• 2018: The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) updates its recommendations, strongly favoring Shingrix over Zostavax for immunocompetent adults aged 50 and older.

Vaccination fundamentally reduces the likelihood of developing shingles and, crucially, significantly lowers the risk of developing PHN if shingles does occur.

The Mechanism: Unpacking "Inflammaging" and Immune Modulation

One of the most compelling aspects of the USC study’s findings is the insight it provides into the potential biological mechanisms at play. Vaccinated participants, on average, exhibited lower levels of inflammation. This is critical because chronic, low-grade inflammation is now recognized as a fundamental driver of accelerated biological aging and a key contributor to numerous age-related diseases. Researchers often refer to this persistent, systemic inflammation as "inflammaging."

Inflammaging is not an acute, protective immune response but rather a smoldering, insidious process characterized by elevated levels of pro-inflammatory cytokines (signaling molecules) in the body. It is implicated in the pathogenesis of cardiovascular disease, type 2 diabetes, neurodegenerative disorders like Alzheimer’s and Parkinson’s, various cancers, sarcopenia (age-related muscle loss), frailty, and cognitive decline. The origins of inflammaging are multifactorial, including accumulated cellular damage, dysfunctional mitochondria, senescent cells (cells that stop dividing but remain metabolically active, secreting inflammatory factors), and persistent viral infections.

Jung Ki Kim elaborates, "By helping to reduce this background inflammation—possibly by preventing reactivation of the virus that causes shingles, the vaccine may play a role in supporting healthier aging." The hypothesis is that by preventing VZV from reactivating and causing shingles, the vaccine reduces a significant inflammatory burden on the immune system. When VZV reactivates, it triggers a strong immune response, which, while necessary to control the infection, also contributes to systemic inflammation. Preventing this reactivation could thus alleviate a chronic source of immune stress and inflammation, thereby slowing down the processes associated with biological aging.

This theory aligns with growing evidence that vaccines may offer broader health effects beyond their targeted infection prevention. Earlier studies cited by Professor Kim have already linked adult vaccines, including shingles and influenza shots, to lower risks of dementia and other neurodegenerative diseases. These observations suggest a common thread: by modulating immune responses and reducing inflammatory loads, vaccines could be acting as systemic health promoters.

Enduring Benefits: A Long-Term Investment in Health

Further reinforcing the robustness of their findings, the USC researchers investigated the longevity of the vaccine’s effects. They analyzed data based on how long ago participants had received their shingles vaccine. The results were highly encouraging: individuals who had been vaccinated four or more years prior to providing a blood sample still demonstrated slower epigenetic aging, slower transcriptomic aging, and better overall biological aging scores compared to their unvaccinated counterparts. This suggests that the potential benefits of shingles vaccination are not fleeting but may persist for several years, offering a long-term investment in healthy aging.

Eileen Crimmins emphasized this point: "These findings indicate that shingles vaccination influences key domains linked to the aging process. While further research is needed to replicate and extend these findings, especially using longitudinal and experimental designs, our study adds to a growing body of work suggesting that vaccines may play a role in healthy aging strategies beyond solely preventing acute illness."

Broader Impact and Future Directions

This study represents a pivotal moment in gerontological research and public health. If confirmed by subsequent longitudinal and experimental studies, including randomized controlled trials (the gold standard for establishing causality), the implications are profound.

• Public Health Recommendations: It could strengthen existing recommendations for shingles vaccination, providing an additional, compelling reason for older adults to get vaccinated—not just to avoid shingles, but to potentially slow down the very process of aging itself. Public health campaigns could highlight these broader benefits, potentially increasing vaccine uptake.
• Geriatric Medicine: Clinicians might view vaccination as a more holistic intervention, contributing to overall health and resilience in older patients. It could become an integral part of personalized healthy aging plans.
• Research into Non-Specific Vaccine Effects: The study fuels further investigation into the "non-specific effects" of vaccines. This field explores how vaccines, beyond conferring immunity to specific pathogens, might also enhance the immune system’s general capacity to fight other infections or modulate inflammatory pathways. Similar research is ongoing for vaccines like the BCG vaccine (against tuberculosis) and influenza vaccines, which have shown unexpected protective effects against various non-communicable diseases.
• Economic and Societal Benefits: Slowing biological aging, even modestly, could have enormous societal and economic benefits. A healthier aging population would lead to reduced healthcare costs associated with chronic age-related diseases, increased productivity, and an improved quality of life for millions.

While the current study establishes a strong association, it is crucial to reiterate the call for further research. Longitudinal studies will track individuals over time to observe changes in biological aging markers post-vaccination, providing more direct evidence of causality. Experimental designs, such as randomized controlled trials where participants are randomly assigned to receive the vaccine or a placebo, would offer the most definitive proof. These future studies will also aim to elucidate the precise biological mechanisms through which the shingles vaccine exerts its systemic effects, perhaps uncovering novel pathways related to immune cell function, cellular senescence, or even microbiome modulation.

In conclusion, the USC Leonard Davis School of Gerontology’s research adds a compelling chapter to the evolving understanding of vaccines. No longer solely viewed as shields against specific pathogens, adult vaccinations, particularly against shingles, may emerge as powerful tools in the broader strategy of promoting healthy aging and potentially extending healthspan by modulating our biological clocks. As Jung Ki Kim aptly summarizes, "While the exact biological mechanisms remain to be understood, the potential for vaccination to reduce inflammation makes it a promising addition to broader strategies aimed at promoting resilience and slowing age-related decline." The humble shingles shot may indeed be a surprising key to unlocking a longer, healthier future.

About the Study

The study, titled "Association between shingles vaccination and slower biological aging: Evidence from a U.S. population-based cohort study," was officially published in the prestigious Journals of Gerontology, Series A: Biological Sciences and Medical Sciences on January 20, 2026. This significant work received crucial support from the National Institute on Aging at the National Institutes of Health (P30 AG017265). The foundational data utilized, the Health and Retirement Study, is itself a testament to long-term investment in health research, being supported by the National Institute on Aging (U01AG009740).